Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fluorescence properties of methylene blue conjugated to normal/cancerous human tissues for spectral discrimination of breast cancer stages (I-IV).

Biomedical optics express·2026

Same author

Finasteride-loaded phospholipid-bile salt mixed micelles for targeted follicular delivery in androgenetic alopecia.

Journal of drug targeting·2026

Same author

Botulinum Toxin Vascular Effectiveness: Low or High Doses?

Aesthetic plastic surgery·2026

Same author

Left Atrial Appendage Aneurysm (LAAA): an updated descriptive systematic review of 25 contemporary cases (2023-2025).

BMC cardiovascular disorders·2026

Same author

Virtual Histology Staining of Skin Tissue using Ex Vivo Confocal Microscopy and Deep Learning.

Journal of biomedical physics & engineering·2025

Same author

Non-invasive detection of choroidal melanoma via tear-derived protein corona on gold nanoparticles: a machine learning approach.

Scientific reports·2025

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Nanotechnology-based PD-L1 siRNA codelivery systems for improving cancer immunotherapy.

Naghmeh Jabarimani¹, Mohammad Saleh Sadeghi¹, Maryam Edalat²

¹Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Journal of Drug Targeting

|December 17, 2025

Summary

Small interfering RNA (siRNA) nanoparticles offer targeted cancer immunotherapy by silencing Programmed death-ligand 1 (PD-L1). This approach enhances combination therapies, improving treatment efficacy and reducing side effects compared to antibody-based methods.

Keywords:

PD-L1 siRNA codelivey immunotherapy lipidic nanoparticle polymeric nanoparticle

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Related Experiment Videos

Last Updated: Jan 8, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Area of Science:

Oncology
Immunology
Nanotechnology

Background:

Immune checkpoint blockade targeting the PD-1/PD-L1 axis revolutionized cancer therapy but faces limitations like off-target effects and limited efficacy in monotherapy.
Antibodies lack specificity and only target cell-surface proteins, while intracellular PD-L1 can evade immune surveillance.

Purpose of the Study:

To review nanoparticle-based strategies for codelivering PD-L1 siRNA with other therapeutic agents for enhanced cancer immunotherapy.
To discuss the mechanisms of PD-L1-mediated tumor immune evasion and how siRNA can overcome these.

Main Methods:

Review of polymer and lipid nanoparticles for codelivery of PD-L1 siRNA and other therapeutics.
Analysis of nanoparticle properties for tumor targeting, responsiveness, and versatility in combination therapy.

Main Results:

Nanoparticles can overcome RNA delivery challenges, enabling targeted delivery of PD-L1 siRNA.
Codelivery systems show promise for combinatorial immunotherapy, potentially improving efficacy and reducing systemic toxicity.

Conclusions:

Nanoparticle-based combinatorial immunotherapy, particularly with PD-L1 siRNA, presents a promising strategy to overcome limitations of current treatments.
Further research and clinical translation are needed to realize the full potential of these advanced therapeutic platforms.